Pts with advanced/metastatic NSCLC;SHR-1701 mono; Treatment-naïve NSCLC with PD-L1+, N=57; EGFR TKIs treated or no standard EGFR TKIs were available NSCLC, N=41; CPIs treated pts who had received up to 3 previous lines of treatments, N=33;. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.